Abstract: The present disclosure provides compositions and methods for treating or preventing macular degeneration in a subject. The disclosure also provides compositions and methods for preserving organs and tissues for transplantation, and for preventing cellular injury in organs or in subjects.

Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.

Abstract: Provided are compounds for the treatment of neurological diseases or injuries, including neurodegenerative diseases, stroke, trauma, epilepsy, acute and chronic kidney injuries, diabetes mellitus, and/or seizures. In some embodiments, derivatives of vitamin K are provided.

Abstract: The present disclosure provides methods of producing hybrid Th1/Th17 cells. Also provided herein are methods of treating cancer comprising targeting the CD38-mediated metabolic axis.

Abstract: The present disclosure provides E2F5 mimetic polypeptides. Further provided are methods for the treatment of cancer, such as head and neck cancer, comprising administering the E2F5 mimetic polypeptides alone or in combination with an additional anti-cancer therapy, such as a chemotherapeutic.

Abstract: The present invention provides for methods of producing human monoclonal antibodies to human nucleolin, cells producing such antibodies, and the antibodies themselves. Also provided are methods of using the antibodies in diagnosing and treating malignant and non-malignant diseases wherein cells that express nucleolin on the cell surface contribute to the pathophysiology of the disease.

Abstract: Provided herein are methods for the production of activated CD26high T cells by co-stimulation with inducible coactivator (ICOS). Further provided are methods for treatment of cancer by administration of the of activated CD26high T cells as an adoptive T cell therapy.

Abstract: Cells, such a T-cells, are provided that comprise cytokine receptors having increased activity in response to their ligand. For example, cell can comprise IL-2 and/or IL-15 receptors having increased surface expression or signaling activity. Cells of the embodiments have a significant growth advantage in the presence of cytokines and can be used, e.g., for enhanced adoptive cell transfer therapies.

Abstract: Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.

Abstract: The invention provides anti-fibrotic peptides derived from the C-terminal region of the MET receptor tyrosine kinase. Polynucleotides encoding these peptides, host cells transformed with the polynucleotides, and methods of using these peptides and polynucleotides are included in the invention. Uses of these peptides, polynucleotides and expression vectors include the treatment of fibrosis in a subject.

Abstract: The present invention relates to compounds of formula (I): including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.

Abstract: Provided herein are methods and compositions for the treatment of cancer comprising the combined administration of an anti-sMIC antibody and an immune checkpoint inhibitor. Methods and compositions for treating colitis with antibodies are also provided. Also provided herein are methods of predicting a response to an anti-sMIC antibody or immune checkpoint inhibitor therapy by measuring the level of serum sMIC in a subject.

Abstract: Embodiments disclosed herein relate to methods and apparatus for cell block preparation of cytology specimens. Specific embodiments relate to methods and apparatus for formalin fixed paraffin embedded cell block preparation of cytology specimens.

Abstract: Isolated or recombinant monoclonal antibodies that bind to GARP are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. Further provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of an anti-platelet agent and a T cell therapy.

Abstract: The present invention relates to an adoptive T cell therapy using cells generated by genetically or biochemically reprogramming T cells to produce T memory stem cells (Tscm) that persist longer in vivo and are superior anti-tumor effector cells.

Abstract: A cranial anchor system configured to attach to an opening in a cranium includes an anchor member. The anchor member has a middle anchor portion and a lower anchor portion coupled to and disposed in a downward direction relative to the middle anchor portion. The lower anchor portion has a plurality of contact members, each of which have a leg that extends at least partially in the downward direction, a tab connected to the leg, and a rib disposed between the leg and the tab. The system further includes an outer sheath and an inner sheath disposed within the outer sheath and slidable relative to the outer sheath.

Abstract: A declogging assembly (20) is configured for use with a suction conduit (10). The suction conduit has a head (14) at a first end (15) and a vacuum tube connection (16) at a second end (17). The assembly includes a body (30). The body defines a first aperture (32), a second aperture (34), and a third aperture (36). The assembly also includes a plug (40) disposed within the body (30). The plug has a surface (42) configured to contact the head (14) of the suction conduit (10) so as to move the plug from a first position, in which the first aperture (32) is in fluid communication with the second aperture (34), to a second position, in which the first aperture (32) is in fluid communication with the third aperture (36). The assembly (20) also includes a biasing member (50) configured to bias the plug into the first position.

Abstract: Disclosed are methods for treating disorders associated with dopamine receptor activity. In some embodiments, the disclosed methods include assaying the nucleic acid from a subject for the genotype of the variable number tandem repeats (VNTR) polymorphism in the dopamine transporter DAT1/SLC6A3 gene, wherein when one or two alleles for 9 tandem repeats is detected a dopamine partial agonist is administered to the subject; and wherein when two alleles for 10 tandem repeats is detected a dopamine modulator is not administered to the subject. Also provided are methods for treating disorders associated with dopamine receptor activity that include genotyping a subject with respect to a COMT polymorphism, a DRD2 polymorphism, a 48-base-pair VNTR polymorphism in DRD4 exon 3, and/or a ANKK1 TaqA1 polymorphism, and methods for detecting susceptibility to dopamine modulator therapy for conditions associated with dopamine receptor activity.

Abstract: Provided are methods for treating alcohol use disorders using opioid receptor antagonists. In some embodiments, the presently disclosed methods include assaying nucleic acid from a subject regarding the subject's genotype with respect to the COMT and OPRM1 genes and administering or not administering an opioid receptor antagonist to the subject on the basis therefore. Also provided are methods for detecting susceptibility to an opioid receptor antagonist therapy for disorders associated with opioid receptor activity and methods for identifying and treating human subjects having susceptibility to opioid receptor antagonist therapies for disorders associated with opioid receptor activity.

Abstract: In some aspects, the present invention provides compounds of the formula (IV), wherein the variables are as defined herein, which may be used as inhibitors of histone demethylase or spermine oxidase. Also provided herein are pharmaceutical compositions of the compounds and methods using the compounds in the treatment of diseases such as cancer and cardiovascular disease.